Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
In our second monthly digest of ‘business of science’ articles from Springer Nature research journals, magazines and supplements, we delve into the history of cystic fibrosis research, celebrate two Nobel prize–winning CRISPR gene editing pioneers and examine big pharma’s interest in antibody–drug conjugates and exosomes.
Montreal-based Inversago Pharma is developing a portfolio of peripherally-acting cannabinoid receptor-1 (CB1) inverse agonists, including its lead candidate INV-101, in development for the treatment of the rare genetic disorder Prader-Willi syndrome (PWS), NASH and other conditions.
The CanVirex platform deploys the oncolytic properties of recombinant measles vectors for innovative cancer treatments. In addition it has now provided a novel COVID-19 vaccine candidate that is approaching clinical trials.